TEP et tumeurs endocrines

Medecine Nucleaire

Volumn 24, Issue 5, 2000, Pages 275-282

  Rigo, Pierre ^a   Belhocine, T ^b   Hustinx, R ^b   Foidart Willems, J ^b  

^a UNIVERSITY OF LIÈGE   (Belgium)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0000271880     PISSN: 09281258     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Bloom A.D., Adler L.P., Shuck J.M. Determination of malignancy of thyroid nodules with positron emission tomography. Surgery 1993; 114: 728-734.
2. Adler L.P., Bloom A.D. Positron emission tomography of thyroid masses. Thyroid 1993; 3: 195-200.
3. 18F-fluorodeoxyglucose imaging in preoperative diagnosis of thyroid malignancy. Eur J Nucl Med 1998; 13: 502-506.
4. 18F)-2-fluoro-2-deoxy-D-glucose positron emission tomography localizes residual thyroid cancer in patients with negative diagnostic (131)I whole body scans and elevated serum thyroglobulin levels. J Clin Endocrinol Metab 1999; 84: 2291-2302.
5. Schlumberger M.J. Papillary and follicular thyroid carcinoma. N Engl J Med 1998; 338: 297-306.
6. Wong CO, Dworkin HJ. Role of FDG PET in metastatic thyroid cancer. J Nucl Med 1999; 40: 993-994.
7. Grunwald F., Kalicke T., Feine U. et al. Fluorine-18 fluorodeoxyglucose positron emission tomography in thyroid cancer : results of a multicentre study. Eur J Nucl Med 1999; 26: 1547-1552.
8. 131I whole-body scan. J Nucl Med 1999; 40: 986-992.
9. 99mYc-methoxyisobutyl isonitril and 201 Tl scintigraphy for detection of residual thyroid cancer after 131I ablative therapy. J Nucl Med 1999; 40: 1434-1440.
10. 99mTc-ses scintigraphy in differentiated cancer. Thyroid 1997; 7: 327-335.
11. Feine U. Fluor-18-deoxyglycose positron emission tomography in differentiated thyroid cancer. Eur J Endocrinol 1998; 138: 492-496.
12. Moog F., Linke R., Tiling R. et al. The influence of TSH levels on the uptake of F-18-FDG in metastatic thyroid carcinoma. Eur J Nucl Med 1999; 26: 1014 (abstract).
13. Maisey M.M., Wahl R.L., Barrington SF. Atlas of clinical positron emission tomography Arnold, London, 1999.
14. Gasparani P., Rubella D., Ferlin G. Potential role of fluorine-18-deoxyglucose (FDG) positron emission tomography (PET) in the staging of primitive and recurrent medullary thyroid carcinoma. J Endocrinol Invest 1997; 20: 527-530.
15. Neumann D.R., Esselstyn C.B., MacIntyre W.J. et al. Primary hyperparathyroidism : preoperative parathyroid imaging with regional body FDG PET. Radiology 1994; 192: 509-512.
16. Neumann D.R., Esselstyn C.B., Kim E.Y. Recurrent posdtoperative parathyroid carcinoma : FDG-PET and sestamibi-SPECT findings. J Nucl Med 1996; 37: 2000-2001.
17. Melon P., Luxen A., Hamoir E., Meurisse M. Fluorine-18-fluorodeoxyglucose positron emission tomography for preoperative parathyroid imaging in primary hyperparathyroidism. Eur J Nucl Med 1995; 22: 556-558.
18. Sundin A., Johansson C., Hellman P. et al. PET and parathyroid L-(carbon-11) methionine acculumation in hyperparathyroidism. J Nucl Med 1996; 37: 1766-1770.
19. Cook G.J.R., Wong J.C.H., Smellie WJB et al. 11C-methionine PET for patients with persistent or recurrent hyperparathyroidism after surgery. Eur J Endocrinol 1998; 139: 195-197.
20. Shulkin B.L., Koeppe R.A., Francis I.R. et al. Pheochromocytomas that do not accumulate metaiodobenzylguanidine : localisation with PET and administration of FDG. Radiology 1993; 186: 711-715.
21. Shulkin B.L., Thompson N.W., Shapiro B. et al. Pheochromocytomas : Imaging with 2-{Fluorine- 18}fluoro-2-deoxy-D-glucose PET. Radiology 1999; 212: 35-41.
22. Maurea S., Mainolfi C., Bazzicalupo L. et al. Imaging of adrenal tumors using FDG-PET : comparison of benign and malignant lesions. AJR 1999; 173: 25-29.
23. Erasmus J.J., Patz E.F.Jr, Page McAdamms H et al. Evaluation of adrenal masses in patients with bronchogenic carcinoma using 18F-fluorodeoxyglucose positron emission tomography. AJR 1997; 168: 1357-1360.
24. Erasmus J.J., Page McAdams H., Patz E.F.Jr et al. Evaluation of primary pulmonary carcinoid tumors using FDG PET. AJR 1998; 170: 1369-1373.
25. Boland G.W., Goldberg M.A., Lee M.J. et al. Indeterminate adrenal mass in patients with cancer : evaluation at PET with 2-(F-18)-fluoro-2-deoxy-D-glucose. Radiology 1995; 194: 131-134.
26. Lamki L.M. Positron emission tomography, bronchogenix carcinoma and the adrenals. AJR 1997; 168: 1361-1362.
27. Adams S., Baum R., Rink T. et al. Limited value of fluorine-18 fluorodeoxyglucose positron emission tomography for the imaging of neuroendocrine tumours. Eur J Nucl Med 1998; 25: 79-83.
28. Adams S., Baum R.P., Hertel A. et al. Metabolic (PET) and receptor (SPEET) imaging of well- and less well-differentiated tumours : comparison with the expression of the Ki-67 antigen. Nucl Med Com 1998; 19: 641-647.
29. 18F-fluorodeoxyglucose positron emission tomography detect tumors with poor prognosis and aggressive behavior? World J Surg 1998; 22: 588-592.
30. Kulke M.H., Mayer R.J. Carcinoid tumors. N Engl J Med 1999; 340: 858-868.
31. Ahlström H., Eriksson B., Bergström M. et al. Pancreatic neuroendocrine tumors : diagnosis with PET. Radiology 1995; 195: 333-337.
32. De Souza B., Brunetti A., Fulham M.J. et al. Pituitary microadenomas : a PET study. Radiology 1990; 177: 39-44.